| INTRODUCTION
There are no approved medications for the treatment of chronic musculoskeletal pain in cats, and only a limited number of analgesic therapeutics with data about efficacy. [1] [2] [3] [4] [5] Before the studies reported here, we surveyed veterinarians regarding pharmaceuticals and dietary supplements used for the alleviation of chronic pain in the cat. 6 The most frequently prescribed treatment was gabapentin.
Gabapentin, an analogue of the neurotransmitter γ-aminobutyric acid (GABA), is a medication commonly used in human medicine for chronic (maladaptive) pain conditions, such as diabetic neuropathy. 7, 8 The drug currently has United States Food and Drug Administration (USFDA) approval for postherpetic neuralgia, and as an adjunctive therapy for partial onset seizures in humans. It is proposed to alter trafficking of voltage-gated calcium channel subunits 9, 10 which have altered expression levels in rodent neuropathic pain models. 11, 12 No clinical studies have been conducted and published assessing the efficacy of gabapentin for the treatment of chronic pain in cats.
The pharmacokinetics of single oral (10 mg/kg) and intravenous (IV; 4 mg/kg) doses of gabapentin in 6 adult spayed female cats has been described, 13 but no other data are available on the pharmacokinetics of gabapentin in the cat. Due of this paucity of data relevant to the clinical use of the drug, the pharmacokinetics of gabapentin administered via intravenous, oral (both single and long-term), and transdermal routes were investigated in the cat.
| MATERIALS AND METHODS

| Animals
Healthy purpose bred male castrated (5) and female spayed (3) domestic shorthaired cats were used in this study. All cats were 2 years old.
Mean body weight was 4.8 kg, with a SD of AE0.8 kg, corresponding to a median body condition score (BCS) of 5 (4) (5) (6) (7) (8) (9) 
| Instrumentation and drug administration
Venous access ports (VAPs; Companion Port 5, Norfolk Access Technologies) were surgically implanted into the right jugular vein and threaded to the junction of the cranial vena cava and right atrium of all cats as previously described. 14, 15 The port was placed at least 2 weeks before drug administration. This was to facilitate blood sample collection across the multiple phases of the study, and minimize stress to the cats.
On the respective day of drug administration, gabapentin was administered as an IV bolus (5 mg/kg; n = 8) in a cephalic vein, as an oral capsule (10 mg/kg; n = 7), or as a transdermal gel (10 mg/kg; n = 7) applied to the interior ear pinnae. Compounded gabapentin products were prepared according to United States Pharmacopeia (USP) standards <795> and <797>, as appropriate, and placed in a brown bag to protect them from light. 16 Gabapentin for intravenous administration was formulated by adding 0.3 g of gabapentin active pharmaceutical ingredient (API; Letco Medical) to 30 mL of sterile water for injection (SWFI) for a final concentration of 10 mg/mL. The syringe-to-syringe method was used to create a homogenous mixture.
After a 0.2 μm filter was used to sterilize the solution in the clean room, the filter's integrity was assessed via bubble point testing. The compound was then placed in a 30 mL glass vial, and refrigerated until Cats were fasted a minimum of 12 hours before dose administration on sampling days, and were allowed access to food after the 2 hours sample was collected. The single oral dose was administered without any food, and was immediately followed with a 5 mL oral bolus of water. The multiple oral doses were administered with a small amount of canned food (a/d Critical Care, c/d Urinary Care, Hill's Pet Nutrition), including on the sample collection day. The repeated oral phase was started immediately after the 24 hours sample was collected for the single oral administration, and was continued for 14 days. Otherwise, a washout period of at least 3 weeks was observed between study phases (IV and single oral, multiple oral and transdermal).
| Gabapentin analysis
The concentration of gabapentin in feline plasma was quantified with UPLC-MS:MS analysis of extracted samples using prepared calibration
standards. An initial stock solution of 3000 μg/mL was prepared by , and 60 μg/mL were used to calculate intraday accuracies of 103.9%, 85.1%, 89.0%, and 101.6% respectively. Intraday precisions were 7.53%, 3.23%, 7.36%, and 7.71%, respectively. The pregabalin to gabapentin percent recoveries using either the API or the finished product were compared at spiked gabapentin concentrations of 0.05, 0.5, 5, and 60 μg/mL. With a minimum of 3 replicates at each concentration, the average ratios (API/finished product) were 1.08, 0.99, 1.02, and 0.99, respectively. The gabapentin limit of quantitation (LOQ) was determined to be 0.05 μg/mL, as it was the lowest concentration in the standard curve with acceptable accuracy (100 +/− 15%) and precision (<10%). The limit of detection (LOD) was 0.01 μg/mL, as the concentration was repeatedly measureable with a signal to noise ratio of at Separation was achieved at 40 C using a phenyl column (2.1 × 100 mm, 1.7 μm phenyl column, Waters), using mobile phase of A:
water with 0.1% formic acid and B: acetonitrile with 0.1% formic acid at a flow rate of 0.4 mL/min.
| Pharmacokinetic analysis
All pharmacokinetic analyses were performed using commercially 
where AUC oral and AUC IV were the Area Under the Curve after oral and IV administration, respectively; and dose IV and dose oral were the dose for IV and oral administration, respectively. The parameters V1
(central volume of distribution), K10, K12, K21, were estimated by use of the model for IV administration, and V (volume of distribution), K01, and K10 were estimated for both oral administration models.
Other pharmacokinetic parameters were calculated by use of standard pharmacokinetic equations. The Wilcoxon signed-rank test was used to compare pharmacokinetic parameters after single and repeated oral administration of gabapentin.
| RESULTS
The strength of the compounded formulations were reported as (mean AE SD, when appropriate) 99% (n = 1), 99.7 AE 5.9% (n = 3), 98.0 AE 3.5% (n = 3), and 137% (n = 1) of the labeled strengths for the IV, 50 mg capsules, 75 mg capsules, and transdermal gel, respectively.
Internal lab strength measurements indicated strengths of 92.6, 95, and 94.1% for the IV, 50 mg capsule, and 75 mg capsule formulations, respectively (n = 1).
The model that was the best fit for the plasma concentrations of gabapentin after IV administration was a 2-compartment model (Figure 1 ). The actual dose administered ranged from 4.90 to 5.11 mg/kg. Pharmacokinetic parameters are available in Table 1 .
A 1-compartment model with lag time (T lag ) was the best fit for both single oral and repeated oral data (Figures 2 and 3 , respectively).
One cat was removed from study before oral or transdermal dosing because of complications secondary to the VAP. Data for 3 time points after single oral administration were excluded for 1 cat because they were clearly outliers, based on the extrapolation from the pre- The only observed side effect during the study was mildmoderate sedation, noted during the 2 hours after IV administration.
Oral administration of the compounded capsules was well tolerated by all cats, with the majority of cats freely consuming the capsule during the multiple/long term administration phase. Soft Elizabethan collars were placed on all cats after transdermal application of the drug, in order to reduce the likelihood of transfer of the transdermal gel to oral ingestion. Three cats removed these collars at various time points, though they were not observed to have been actively grooming their ears and did not have correlating higher plasma drug concentrations than the other cats.
| DISCUSSION
This report demonstrated that repeated oral dosing does not significantly impact gabapentin pharmacokinetics, and that the drug has poor bioavailability when administered as the transdermal gel compounded for this study.
While our values for clearance and terminal half-lives are comparable to another report after a single IV bolus in cats, our results for the oral dose differ from data in that same report. 13 Most notably, our maximum concentration (C MAX ) was approximately 50% greater than previously reported (7.982 AE 1.053 μg/mL; 4.638-10.550), with a slightly longer half-life (2.95 AE 0.42 hours; 2.52-3.52). These differences may be because of our reported higher bioavailability, higher dosages in some individuals, and differences in sampling sites and times. Ultimately, the reasons for the discrepancies between studies are undetermined.
There are no data for cats that describe the optimum plasma drug concentrations for gabapentin. While previously reported data and modeling suggests a half maximal effective concentration (EC50) ranging from 1.4 and 16.7 μg/mL for treatment of hyperalgesia in the rat 20-22 and 5.4 μg/mL for the treatment of neuropathic pain in man, 23 we cannot determine if these values will apply to cats. Calculation of the average plasma concentration after multiple doses results in a value of 6.11 μg/mL, with median trough concentrations of 2.55 and 1.49 μg/mL for the second-to-last and last dose, respectively. This would suggest that the current prescribing practices (10 mg/kg administered twice daily) would be insufficient to maintain plasma concentrations associated with efficacy in other species. Modeling to determine a potential dose and dosing interval, using a targeted minimum concentration of 5.4 μg/mL and C MAX of 16.7 μg/mL (based on the EC50 reported in man and rat, respectively) results in a suggested dose of approximately 8 mg/kg at an interval of 6 hours. Our data also suggest that gabapentin (as prepared in this study) has minimal transdermal absorption, and is not an appropriate route of administration.
The transdermal vehicle was chosen because of its drug delivery properties, and its common use in practice. 24, 25 These data are relevant given the increasing interest in compounding of transdermal preparations for cats. [24] [25] [26] There were several sources of potential bias or error in our study.
Treatments were administered in a serial order, without randomization. While clearance, volume of distribution, and other pharmacokinetic parameters are not expected to change significantly in healthy adult cats over period of 3 weeks (washout period), unpredictable or uncontrollable factors could have affected our results. Additionally, we wanted to compare the first and last doses in a contiguous dosing Summary pharmacokinetics statistics after administration of gabapentin as a single IV bolus (5 mg/kg; n = 8), a single oral dose (10 mg/kg; n = 7), and repeated oral doses (10 mg/kg; n = 7) Results are presented as median (range). F, bioavailability, or fraction absorbed unchanged; K01, absorption rate constant to the central compartment; K10, elimination rate constant from the central compartment; K12, distribution rate constant from the central (1) to peripheral compartment (2); K21, distribution rate constant from the peripheral (2) to central compartment (1); V1, apparent volume of the central compartment; T LAG, lag time or delay for drug absorption following oral administration; A and B, and α and β = Coefficients and exponents, respectively, in the following equation used describe the drug disposition curve at time t: (A X e-αt) + (B X e-βt), where e is Euler's number (2.7183); T 1/2 , half-life; α T 1/2, plasma or distribution half-life after IV administration; β T 1/2 , elimination half-life after IV administration; AUC, area under the curve for the concentration versus time profile; CL, systemic clearance; C MAX , peak concentration; K01 T 1/2 , absorption half-life after oral administration; K10 T 1/2 , elimination half-life after oral administration; V SS , apparent volume of distribution at steady state, T MAX time to peak concentration. a Statistically significant difference (P = .0052).
FIGURE 2
Gabapentin plasma concentrations after a single oral dose (10 mg/kg) in 7 cats (closed circles) with modeled time-concentration curve (using geometric mean of derived parameters; solid line). Samples were collected at 5, 15, 30, 45, 60, and 90 minutes, followed by collection at 2, 4, 8, 12, and 24 hours after oral administration. Data below the limit of quantitation are excluded While the strengths of the IV solution and oral capsules were within the USP's acceptable range of AE10%, our transdermal gel was not. This resulted in higher than intended doses being administered, though absorption was still poor. It is possible that the transdermal preparations lacked adequate homogenization, which could have affected both drug kinetics during the study, and subsequent strength analysis. Cephalic catheters for IV bolus administration were placed either ipsi-or contralateral to the sampling ports, which could affect the detected plasma concentrations. This risk may be reduced by the placement of the catheter in the cranial vena cava/right atrium, but the risk remains. The use of a finished product (Lyrica) as our internal standard added a confounding factor to our results. We chose this internal standard because of its previous use in the veterinary literature, however, the use of an analytical grade standard would have eliminated this risk. Subsequent comparison of the assay using either the finished product or API revealed satisfactory agreement. Cats were fasted before drug administration, and compounded capsules were administered either with a water bolus (single oral dose) or with a small amount of food (multiple/long term dosing). It is known that gastrointestinal transit time (and therefore, absorption kinetics) are different between the fed and fasted state, as well as among different food particle sizes. 27 The type of meal affects gabapentin absorption in people. 28 There was also not an even distribution of sexes, and
